Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucinda Billingham

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|December 30, 2008
Sorafenib for liver cancer: the horizon broadensPhilip Johnson, Lucinda Billingham
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Potential hazards in the analysis of symptom improvementLucinda Billingham, Michael Cullen
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 3, 2011
Mapping utility scores from the Barthel indexBillingsley Kaambwa, Lucinda Billingham, Stirling Bryan
BMC Research Notes|June 29, 2012
Do the methods used to analyse missing data really matter? An examination of data from an observational study of Intermediate Care patientsBillingsley Kaambwa, Stirling Bryan, Lucinda Billingham
The Lancet. Oncology|February 13, 2016
Research methods to change clinical practice for patients with rare cancersLucinda Billingham, Kinga Malottki, Neil Steven
BMC Medical Research Methodology|July 4, 2013
Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemiaChristina Yap, Andrew Pettitt, Lucinda Billingham
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 30, 2003
Early radiotherapy related morbidityAndrew Hartley, Selvaraj Giridharan, Gulnaz Begum, et al.
BMC Medical Research Methodology|July 22, 2017
Implementing the EffTox dose-finding design in the Matchpoint trialKristian Brock, Lucinda Billingham, Mhairi Copland, et al.
BMC Cancer|July 12, 2021
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell, et al.
Blood|June 22, 2010
The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoireBatoul Pourgheysari, Rachel Bruton, Helen Parry, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|December 30, 2008
Sorafenib for liver cancer: the horizon broadensPhilip Johnson, Lucinda Billingham
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Potential hazards in the analysis of symptom improvementLucinda Billingham, Michael Cullen
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 3, 2011
Mapping utility scores from the Barthel indexBillingsley Kaambwa, Lucinda Billingham, Stirling Bryan
BMC Research Notes|June 29, 2012
Do the methods used to analyse missing data really matter? An examination of data from an observational study of Intermediate Care patientsBillingsley Kaambwa, Stirling Bryan, Lucinda Billingham
The Lancet. Oncology|February 13, 2016
Research methods to change clinical practice for patients with rare cancersLucinda Billingham, Kinga Malottki, Neil Steven
BMC Medical Research Methodology|July 4, 2013
Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemiaChristina Yap, Andrew Pettitt, Lucinda Billingham
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 30, 2003
Early radiotherapy related morbidityAndrew Hartley, Selvaraj Giridharan, Gulnaz Begum, et al.
BMC Medical Research Methodology|July 22, 2017
Implementing the EffTox dose-finding design in the Matchpoint trialKristian Brock, Lucinda Billingham, Mhairi Copland, et al.
BMC Cancer|July 12, 2021
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell, et al.
Blood|June 22, 2010
The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoireBatoul Pourgheysari, Rachel Bruton, Helen Parry, et al.
Pageof 6